Facia: Funding, Investors & Team (Sep 2026)

Facia is a leading company that specializes in biometric authentication and advanced face recognition technology. They offer a range of innovative solutions to enhance security and enable accurate identification in various situations. A standout feature of their technology is liveness detection, which ensures that the face being verified is real and not being manipulated. By analyzing facial movements, texture, and other factors, their advanced algorithms are able to differentiate between genuine faces and fraudulent attempts using masks, photos, or videos. This helps to prevent identity fraud and maintain the integrity of authentication processes. Facia's face matching capabilities are also highly accurate and efficient. Their 1:1 face matching verifies a person's identity against a known image or template, while their 1:n face matching enables quick and precise identification from a large face database. This is especially useful in scenarios such as border controls and access management systems. Moreover, Facia offers age verification solutions that utilize their advanced facial recognition technology. By analyzing facial features, they can accurately determine an individual's age, ensuring compliance with age-restricted regulations in various industries. To further enhance security, their solutions incorporate iris scan technology, which provides an additional layer of biometric authentication for increased accuracy and reliability. If you are looking for cutting-edge biometric authentication solutions that enable secure and efficient identification systems while safeguarding against fraud, choose Facia.

Facia has raised $1.1M across 1 round on record. The most recent is a Seed of $1.1M announced in Jul 2023.

Facia's most recent funding round on record is a Seed of $1.1M, announced in Jul 2023.

Hugo Cordova Rivera is listed as CEO at Facia.

Facia is based in London, England, United Kingdom.

Facia is in the 101-250 employee band.

Facia's latest round of $1.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.